Introduction: We sought to conduct a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the impact of myo-inositol on oocyte and embryo quality in women undergoing assisted reproduction.
Methods: The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist (registration number: CRD42023433328). Studies were identified by searching PubMed, Cochrane Library, Google Scholar, Scopus, Embase, and ClinicalTrials databases.
Results: Eight RCTs were included for qualitative analysis reporting on 820 participants. Four meta-analyses were performed. Numbers of retrieved oocytes in comparison of intervention and control group were higher in inositol group (mean difference [MD] = 0.41, 95% CI: 0.05-0.77, p = 0.02). Meta-analysis of two studies comparing numbers of oocytes among poor ovarian responder patients showed no significant difference between intervention and control group (MD = 0.50, 95% CI: 0.57-1.58, p = 0.36). Miscarriage rate has no statistically significant difference between the treatment and control groups (risk ratios [RRs] = 0.81, 95% CI: 0.20-3.32, p = 0.77). Inositol played no role in improving clinical pregnancy rates; there was no significant difference between the intervention group and the control group (RR = 1.41, 95% CI: 0.88-2.25, p = 0.15).
Conclusion: Thus, we did not find any benefits of using myo-inositol on oocyte and embryo quality in women undergoing reproductive technologies. Further studies are needed to assess efficacy, safety, and high compliance by female patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000540023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Biology, Parand Branch, Islamic Azad University, Bahonar Blvd, Tehran, Iran.
The research investigated the capacity of myo-inositol (MI) in order that it improves biochemical markers in serum and follicular fluid and, ultimately, intracytoplasmic sperm injection (ICSI) outcomes of women with PCOS. Sixty infertile patients with PCOS, who were undergoing ovulation induction for ICSI, were randomly divided to two groups. The MI group received 2000 mg myo-inositol + 1 mg folic acid twice a day for 6 weeks with starting the ICSI cycle.
View Article and Find Full Text PDFComparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis.
J Ovarian Res
December 2024
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Purpose: To compare the efficacy and safety of metformin, anti-obesity agents, and inositol with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Methods: A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for studies published in English up to October 26, 2024.
Article Synopsis
- Myo-inositol (MYO) and D-chiro-inositol (DCI) are key inositol isomers crucial for cell signaling, with MYO being the most prevalent in nature and DCI derived from MYO through insulin-dependent processes.
- In women with conditions like PCOS, the MYO/DCI ratio shifts significantly, impacting oocyte quality and contributing to increased androgen levels, while MYO supplementation can enhance embryo quality in fertility treatments.
- Inositol may also help mitigate gestational diabetes risks during pregnancy, suggesting that dietary supplementation could be a beneficial approach for improving female fertility and supporting healthy pregnancies.
Brain-Region-Specific Differences in Protein Citrullination/Deimination in a Pre-Motor Parkinson's Disease Rat Model.
Int J Mol Sci
October 2024
Pathobiology and Extracellular Vesicles Research Group, School of Life Sciences, University of Westminster, London W1W 6XH, UK.
Article Synopsis
- - Recent research highlights the significance of citrullination/deimination by peptidylarginine deiminases (PADs) in the early stages of Parkinson's disease (PD), focusing on their potential as biomarkers.
- - A study using a rat model of pre-motor PD identified significant differences in citrullinated proteins across six brain regions (cortex, hippocampus, striatum, midbrain, cerebellum, and olfactory bulb) compared to controls, with the most alterations found in the cortex and hippocampus.
- - Pathway analysis revealed unique KEGG pathways related to neurological, metabolic, immune, and hormonal functions in PD brains, some of which were specific to the disease state while others
Eicosatrienoic acid enhances the quality of in vitro matured porcine oocytes by reducing PRKN-mediated ubiquitination of CISD2.
Theriogenology
December 2024
Department of Animal Science, College of Agriculture, Yanbian University, Yanji, 133002, China; Jilin Provincial Key Laboratory of Transgenic Animal and Embryo Engineering, Yanji, 133002, China. Electronic address:
Oocytes and early embryos are exposed to many uncontrollable factors that trigger endoplasmic reticulum (ER) stress during in vitro culture. Prevention of ER stress is an effective way to improve the oocyte maturation rate and oocyte quality. Increasing evidence suggests that dietary intake of sufficient n-3 polyunsaturated fatty acids (PUFAs) is associated with health benefits, particularly in the domain of female reproductive health.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!